Table 2.
Pathology details
| Standard surgery (N=683)* | Lymphadenectomy (N=686)* | ||
|---|---|---|---|
| Extent of tumour | |||
| Confined to corpus uteri | 553 (81%) | 538 (79%) | |
| Spread beyond corpus uteri | 128 (19%) | 146 (21%) | |
| Extension to endocervical glands | 33 (27%) | 34 (24%) | |
| Extension to cervical stroma | 53 (43%) | 57 (40%) | |
| Extension beyond uterus | 38 (31%) | 52 (36%) | |
| Unknown | 4 | 3 | |
| Unknown | 2 | 2 | |
| Histology | |||
| Endometriod | 545 (80%) | 541 (79%) | |
| Adenocarcinoma NOS | 46 (7%) | 37 (5%) | |
| Clear cell | 10 (1%) | 17 (2%) | |
| Papillary serous | 21 (3%) | 32 (5%) | |
| Squamous | 6 (1%) | 5 (1%) | |
| Mucinous | 1 (<1%) | 4 (1%) | |
| Mixed epithelial stromal | 7 (1%) | 8 (1%) | |
| Sarcoma | 10 (1%) | 9 (1%) | |
| Other epithelial | 4 (1%) | 6 (1%) | |
| Mixed epithelial | 31 (5%) | 25 (4%) | |
| Unknown | 2 | 2 | |
| Differentiation or grade | |||
| Well (G1) | 225 (33%) | 213 (31%) | |
| Moderate (G2) | 300 (44%) | 290 (43%) | |
| Poor (G3)† | 139 (20%) | 158 (23%) | |
| Not applicable‡ | 16 (2%) | 16 (2%) | |
| Unknown | 3 | 9 | |
| Depth of invasion | |||
| Endometrium only | 96 (14%) | 89 (13%) | |
| Inner half of myometrium | 369 (55%) | 310 (46%) | |
| Outer half of myometrium | 212 (31%) | 274 (41%) | |
| Unknown | 6 | 13 | |
| Lymphovascular permeation | |||
| Present | 125 (19%) | 140 (22%) | |
| Not present | 407 (63%) | 377 (59%) | |
| Not stated | 111 (17%) | 127 (20%) | |
| Unknown | 40 | 42 | |
| Nodal involvement (if nodes harvested) | |||
| Yes | 9 (27%) | 54 (9%) | |
| No | 23 (72%) | 560 (91%) | |
| Unknown | 0 | 1 | |
| Number of involved nodes | |||
| 1 | 5 (56%) | 28 (52%) | |
| 2 | 3 (33%) | 12 (22%) | |
| 3 | 0 | 6 (11%) | |
| 4 | 0 | 2 (4%) | |
| 5 | 1 (11%) | 4 (7%) | |
| 6 | 0 | 2 (4%) | |
| Position of involved nodes | |||
| Unilateral | 6 (67%) | 31 (58%) | |
| Bilateral | 2 (22%) | 19 (36%) | |
| Para-aortic | 1 (11%) | 3 (6%) | |
| Unknown | 0 | 1 | |
| FIGO stage§ | |||
| IA | 88 (13%) | 84 (12%) | |
| IB | 318 (47%) | 261 (39%) | |
| IC | 147 (22%) | 187 (28%) | |
| IIA | 33 (5%) | 34 (5%) | |
| IIB | 53 (8%) | 57 (8%) | |
| III/IV | 38 (6%) | 52 (8%) | |
| Unknown | 6 | 11 | |
Data are number (%) or number. NOS=not otherwise specified.
*
Excludes patients whose pathology details did not confirm endometrial cancer: 39 women (21 standard surgery group, 18 lymphadenectomy group) who had no other tumour in the surgical specimen; atypical hyperplasia; or cervical, ovarian, or colorectal cancer.
†
Including clear cell and serous papillary.
‡
Sarcoma and mixed epithelial sarcoma.
§
FIGO IIIC is not included here. Women with positive lymph nodes are classified irrespective of nodal status.